Prasugrel + Clopidogrel for Coronary Artery Disease
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial explores whether switching to a low dose of prasugrel (an antiplatelet medication) reduces platelet reactivity more effectively than the usual dose of clopidogrel in individuals with coronary artery disease who have had a stent placed. It targets those at higher risk of both bleeding and cardiovascular issues. Individuals who have had a stent placed and have been on a daily regimen of aspirin and clopidogrel for over a month may qualify for this study. As a Phase 4 trial, this research aims to understand how the already FDA-approved and effective treatment benefits a broader range of patients.
Will I have to stop taking my current medications?
If you are currently taking clopidogrel and low-dose aspirin as part of your treatment, you may need to switch from clopidogrel to prasugrel for this trial. The protocol does not specify stopping other medications, but you should discuss your current medications with the trial team.
What is the safety track record for prasugrel and clopidogrel?
Research shows that clopidogrel is generally easy for most people to tolerate. One study found it reduced major bleeding from 1.54% to 0.41% over a year. Clopidogrel also lowers the risk of serious heart problems, such as heart attacks and issues with stents after procedures.
Prasugrel is another treatment option considered safe for people with heart conditions. Studies have found that using a lower dose of prasugrel reduces bleeding risks compared to longer treatment periods, without increasing the chance of heart-related problems.
Both treatments have demonstrated safety. However, because individuals can respond differently, discussing these options with a healthcare provider is important.12345Why are researchers enthusiastic about this study treatment?
Most treatments for coronary artery disease, like clopidogrel-based dual antiplatelet therapy (DAPT), aim to prevent blood clots but come with a risk of bleeding. However, prasugrel stands out because it offers a potentially more balanced approach to managing both bleeding and ischemic risks, especially when used in a low-dose DAPT regimen. Researchers are excited about prasugrel because it might offer better protection for patients who are at high risk for both bleeding and ischemic events. By targeting these dual risks more precisely, prasugrel could provide an alternative for patients who need effective blood clot prevention without significantly increasing their risk of bleeding.
What evidence suggests that this trial's treatments could be effective for coronary artery disease?
In this trial, participants will be assigned to different treatment arms to evaluate the effectiveness of dual antiplatelet therapy (DAPT) using either clopidogrel or prasugrel. Research has shown that combining clopidogrel with another blood-thinning medication can effectively reduce serious health issues, including lowering major bleeding from 1.54% to 0.41% over a year. It also outperforms aspirin alone after heart procedures to open blocked arteries. Meanwhile, this trial studies prasugrel, particularly at a lower dose, for its potential to reduce the risk of serious problems by 49% in people with acute coronary syndrome (ACS). This suggests that prasugrel might better balance preventing clots and reducing bleeding risk. Both treatments in this trial aim to manage heart conditions by lowering the chances of heart attacks and strokes.12367
Who Is on the Research Team?
Dominick J Angiolillo, MD, PhD
Principal Investigator
University of Florida College of Medicine - Jacksonville
Luis Ortega-Paz, MD, PhD
Principal Investigator
University of Florida College of Medicine - Jacksonville
Are You a Good Fit for This Trial?
This trial is for heart disease patients with high bleeding and ischemic risk who have undergone a procedure called PCI. They must meet specific criteria indicating they're at dual-risk for complications post-PCI.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants are randomized to receive either low-dose prasugrel-based DAPT or continue with clopidogrel-based DAPT
Follow-up
Participants are monitored for platelet reactivity and safety after treatment
What Are the Treatments Tested in This Trial?
Interventions
- Clopidogrel
- Prasugrel
Trial Overview
The study tests if switching from standard-dose Clopidogrel to low-dose Prasugrel is better than continuing on Clopidogrel in managing platelet reactivity, which affects blood clotting, in high-risk heart patients after PCI.
How Is the Trial Designed?
Patients deemed at high risk for both bleeding and ischemic risk randomized to receive low-dose prasugrel-based DAPT. High bleeding riks will be defined according to the Academic Research Consortium definition, while high ischemic risk will be defined as those patients with an ABCD-GENE score of 10 or higher.
Patients deemed at high risk for both bleeding and ischemic risk randomized to continue clopdiogrel-based DAPT. High bleeding riks will be defined according to the Academic Research Consortium definition, while high ischemic risk will be defined as those patients with an ABCD-GENE score of 10 or higher.
Patients deemed at high risk for both bleeding but not at high risk for ischemic events being actively treated with clopidogrel-based DAPT as per standard of care. High bleeding riks will be defined according to the Academic Research Consortium definition.
Find a Clinic Near You
Who Is Running the Clinical Trial?
University of Florida
Lead Sponsor
Citations
Dual Antiplatelet Therapy in Coronary Artery Disease - PMC
The results demonstrated that prolonged DAPT with either dose of ticagrelor reduced ischemic events (for 60 mg dose HR = 0.84; 95% CI 0.74–0.95; p = 0.004) MACE ...
Clopidogrel for Long-Term Secondary Prevention After ...
Net adverse clinical event rate was significantly reduced along with a significant reduction in major bleeding from 1.54% to 0.41% at 12 months ...
Long‐Term Outcomes and Duration of Dual Antiplatelet ...
DAPT discontinuation after 9 months following PCI was associated with lower risks of death (HR, 0.93 [95% CI, 0.88–0.99]), cardiac death (HR, ...
4.
acc.org
acc.org/About-ACC/Press-Releases/2025/03/30/15/43/Clopidogrel-Outperforms-Aspirin-MonotherapyClopidogrel Outperforms Aspirin Monotherapy Following PCI
After a median of 2.3 years, 4.4% of those taking clopidogrel and 6.6% of those taking aspirin experienced the composite primary endpoint. This ...
Extended Clopidogrel Monotherapy vs DAPT in Patients ...
This randomized clinical trial evaluates clopidogrel monotherapy vs dual antiplatelet therapy in patients with acute coronary syndromes ...
Versus Short-Term Dual Antiplatelet Therapy Duration in ...
DAPT>12-month versus ≤12-month DAPT was associated with a significant reduced risk of 3-year primary outcome (2.6% versus 4.6%; adjusted hazard ...
pci patients: An updated systematic review and meta-analysis
Clopidogrel is associated with reduction in major adverse cardiovascular events as compared to aspirin in post-PCI patients.
Other People Viewed
By Subject
By Trial
Related Searches
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.